16 citations
,
December 2012 in “Bioinformation” This study suggests that natural molecules like curcumin, EGCG, barringtozenol, and finasteride may be effective inhibitors for VEGFR, potentially offering a cancer chemoprevention alternative to pazopanib.
December 2025 in “Biomedicines” This source reviews the common skin-related side effects of tyrosine kinase inhibitors in treating endocrine cancers and emphasizes that proactive, multidisciplinary management can effectively control these adverse events without compromising cancer treatment efficacy.
508 citations
,
June 2009 in “Current drug metabolism” This review details the skin and hematological toxicities of tyrosine kinase inhibitors like erlotinib, gefitinib, and imatinib, and highlights ongoing concerns about cardiac toxicity, reporting no new clinical findings.
30 citations
,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings” This study found that in vitro treatments with 5alpha-reductase inhibitors and androgen receptor antagonists strongly stimulate VEGF expression in dermal papilla cells.
This review discusses the androgen-dependent and genetic factors of androgenetic alopecia, highlighting differences in its manifestation between men and women, and reports no new clinical results.